|Articles|October 19, 2011

ONCOLOGY Nurse Edition Vol 25 No 10
Volume 25
Issue 10

Suggested Reading for a Geriatric Oncology Nursing Journal Club

Black B, Herr K, Fine P, et al: The relationship between pain, nonpain symptoms, and quality of life measures in older adults with cancer receiving hospice care. Pain Med 12(6):880–889, 2011.

Black B, Herr K, Fine P, et al: The relationship between pain, nonpain symptoms, and quality of life measures in older adults with cancer receiving hospice care. Pain Med 12(6):880–889, 2011.

Cesari M, Colloca G, Cerullo F, et al: Onco-geriatric approach for the management of older patients with cancer. J Am Med Dir Assoc 12(2):153–159, 2011.

Clegg A, Young JB: Which medications to avoid in people at risk of delirium: A systematic review. Age Aging 40(1):23–29, 2011.

Dilworth JA, Thomas K, Sawkins N, et al: Use of the distress thermometer for the elderly in the identification of distress and need in nursing and care homes. Aging Mental Health 15(6):756–764, 2011.

Haddad A, Shepard D: Geriatric oncology and palliative medicine. Semin Oncol 38(3):362–366, 2011.

Klepin HD, Danhauer SC, Tooze JA, et al: Exercise for older adult inpatients with acute myelogenous leukemia: A pilot study. J Geriatr Oncol 2(1):11–17, 2011.

Articles in this issue

about 15 years ago

Article

News of Note

about 15 years ago

Article

Integrative Medicine Conference Calendar

about 15 years ago

Article

HE4 Biomarker Test Is Approved for Use in Risk of Ovarian Malignancy Algorithm (ROMA)

about 15 years ago

Article

The Complexity of Hereditary Cancer Syndromes

about 15 years ago

Article

Vemurafenib, a BRAF Inhibitor for Patients With Unresectable or Metastatic Melanoma and V600E-Mutated BRAF Protein

about 15 years ago

Article

Coenzyme Q10

about 15 years ago

Article

Elder Spousal Grief in the Context of Cancer Caregiving

about 15 years ago

Article

Our 9/11 Cancer Nursing Connection

about 15 years ago

Article

October Is National Breast Cancer Awareness Month

about 15 years ago

Article

Counseling Women at High Risk of Ovarian or Endometrial Cancer

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Cancer of the urinary bladder and bladder wall, cutaway side view. | © Judith - stock.adobe.com.

November 9th, 2026

Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC

Israel approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS, expanding access beyond the US, UK, EU, Saudi Arabia, and UAE.

At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.

November 9th, 2026

Comparing Liver Cancer Prevention Strategies in Japan and the US

At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.

Liver cancer, Hepatocellular Carcinoma (HCC), conditions, causes and treatment. 3d illustration | Image Credit: © Crystal light - stock.adobe.com

November 9th, 2026

Top 3 Poster Takeaways in Liver Cancer Care From The Liver Meeting 2026

Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.

A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.

November 9th, 2026

Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC

A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.

$In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.$

November 9th, 2026

Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC

In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.

November 9th, 2026

PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer

Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.